Sterling Biotech (Delisted) share news and announcements
BSE: 512299Pharmaceuticals & Biotechnology
Formerly Sterling Tea and Industries
Last traded ₹0.70 on 5 Nov 2018
Delisted on 3 Mar 2023.
Sterling Biotech dividends
7 filed, newest first.
Jun 2011
2 Jun · Dividend
Board of Directors of the Company at its meeting held on May 31, 2011 has recommended 50% (Rs. 0.50 per equity share of F.V. of Re.1/- each) dividend on the equity shares for the financial year ended December 31, 2010 subject to approval of the members at the ensuing Annual General Meeting.
May 2011
31 May · Dividend
Board of Directors of the Company at its meeting held on May 31, 2011, inter alia, has recommended 50% [Rs. 0.50 per equity share of F.V. ....
Mar 2010
31 Mar · Dividend
Board of Directors of the Company at its meeting held on March 31, 2010, has recommended 50% (Rs. 0.50 per equity share of F.V. of Re. 1/- ....31 Mar · Dividend
Board of Directors at their meeting held on March 31, 2010 has recommended 50% (Rs. 0.50 per equity share of F.V of Re. 1/- each) dividend on the equity shares for the financial year ended December 31, 2009 subject to approval of the members at the ensuing Annual General Meeting.
Mar 2009
31 Mar · Dividend
Board of Director at its meeting held on March 31, 2009, the Board has recommended 50% (Rs 0.50 per equity share of F.V. of Re. 1 /- each) dividend on the equity shares for the financial year ended December 31, 2008 subject to approval of the members.
Mar 2008
31 Mar · Dividend
Board, at its meeting held on March 31, 2008 has recommended 50% (Rs.0.50 per equity share of FV of Rs.1/-) dividend on the equity shares for the financial year ended December 31, 2007 subject to approval of the members.
Mar 2007
29 Mar · Dividend
Board has recommended 50% (Rs.0.50 per equity shares of FV of Rs.1/-) dividend on the equity shares for the financial year ended 31st December 2006 subject to approval of the members at the ensuing Annual General Meeting of the Company. The Board has also approved on enabling resolution for issue of equity or equity related instruments or any other convertible instrument aggregating up to US$ 300 million, if required in future, as detailed in the resolution. The enabling resolution will be subject to all necessary permissions and approvals as are required at the relevant time and are subject to approval by the members at the ensuing General Meeting of the Company.